{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:04:14Z","timestamp":1784966654051,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CHL, Ahmedabad, India"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Limited supply, cost and potential for severe adverse effects observed with the blood derived rabies immunoglobulin products has led to search for alternative therapies. This issue has been addressed by developing an anti-rabies monoclonal antibody cocktail.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a phase 3, randomized, open-label, noninferiority trial conducted in patients with World Health Organization (WHO) category III exposure with suspected rabid animal. Eligible patients were assigned to either the test arm, TwinrabTM (docaravimab and miromavimab) or the reference arm, human rabies immunoglobulin (HRIG; Imogam\u00ae Rabies-HT), in a ratio of 1:1. The primary endpoint was the comparison of responder rates between the 2 arms assessed as percentage of those with rabies virus neutralizing antibodies titers \u22650.5 IU\/mL on day 14.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 308 patients were equally randomized into the 2 arms. In the per-protocol (PP) population, there were 90.21% responders in the TwinrabTM arm and 94.37% in the HRIG arm. The geometric mean of rapid fluorescent foci inhibition test titers in the PP on day 14 were 4.38 and 4.85 IU\/mL, for the TwinrabTM and HRIG arms, respectively. There were no deaths or serious adverse events reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study confirmed that TwinrabTM is noninferior to HRIG in terms of providing an unbroken window of protection up to day 84. This trial in healthy adults with WHO category III exposure from suspected rabid animal also establishes the safety of TwinrabTM in patients with 1 WHO approved vaccine regimen (Essen).<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trials Registration<\/jats:title><jats:p>CTRI\/2017\/07\/009038.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa779","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T19:11:39Z","timestamp":1591902699000},"page":"e2722-e2728","source":"Crossref","is-referenced-by-count":44,"title":["A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)"],"prefix":"10.1093","volume":"73","author":[{"given":"Kevinkumar","family":"Kansagra","sequence":"first","affiliation":[{"name":"Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[{"name":"Zydus Discovery DMCC, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev Kumar","family":"Mendiratta","sequence":"additional","affiliation":[{"name":"Biologics R&D and Mfg, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Patel","sequence":"additional","affiliation":[{"name":"Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchi","family":"Joshi","sequence":"additional","affiliation":[{"name":"Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Sharma","sequence":"additional","affiliation":[{"name":"Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Parihar","sequence":"additional","affiliation":[{"name":"Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Bhoge","sequence":"additional","affiliation":[{"name":"Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harilal","family":"Patel","sequence":"additional","affiliation":[{"name":"Drug Metabolism and Pharmacokinetic, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kalita","sequence":"additional","affiliation":[{"name":"Biotechnology, Cadila Healthcare Limited, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Munshi","sequence":"additional","affiliation":[{"name":"TN Medical College and BYL Nair Charitable Hospital, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Kurmi","sequence":"additional","affiliation":[{"name":"Shivam Hospital, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchir","family":"Shah","sequence":"additional","affiliation":[{"name":"Medistar Hospital, Himmatnagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gupta","sequence":"additional","affiliation":[{"name":"Subharti Medical College, Meerut, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HiraLal","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Subharti Medical College, Meerut, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Bekkalele","sequence":"additional","affiliation":[{"name":"Mandya Institute of Medical Science, Mandya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RajendraKumar","family":"Verma","sequence":"additional","affiliation":[{"name":"GSVM Medical College, Kanpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Marwari Hospital and Research Centre, Guwahati, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Sharma","sequence":"additional","affiliation":[{"name":"SMS Medical College, Jaipur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Gawande","sequence":"additional","affiliation":[{"name":"Government Medical College, Nagpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chhaya","sequence":"additional","affiliation":[{"name":"Saviour Hospital, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"2021110300345704200_CIT0001","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"2021110300345704200_CIT0002"},{"key":"2021110300345704200_CIT0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11908-016-0540-y","article-title":"Human rabies: a 2016 update","volume":"18","author":"Jackson","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"2021110300345704200_CIT0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(18)30512-7","article-title":"The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study","volume":"19","author":"Hampson","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021110300345704200_CIT0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/tropicalmed4010050","article-title":"Cost savings of using updated Thai Red Cross intradermal regimen in a high-throughput anti-rabies clinic in New Delhi, India","volume":"4","author":"Kundu","year":"2019","journal-title":"Trop Med Infect Dis"},{"key":"2021110300345704200_CIT0006","volume-title":"WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment","year":"2002"},{"key":"2021110300345704200_CIT0007","first-page":"375","article-title":"Elimination of human rabies in a canine endemic province in Thailand: five-year programme","volume":"81","author":"Kamoltham","year":"2003","journal-title":"Bull World Health Organ"},{"key":"2021110300345704200_CIT0008","first-page":"459","article-title":"Demographics of animal bite victims and management practices in a tertiary care institute in Mumbai, Maharashtra, India","volume":"139","author":"Gogtay","year":"2014","journal-title":"Indian J Med Res"},{"key":"2021110300345704200_CIT0009","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/j.vaccine.2010.08.034","article-title":"Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis","volume":"28","author":"Fang","year":"2010","journal-title":"Vaccine"},{"key":"2021110300345704200_CIT0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2021110300345704200_CIT0011","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1016\/j.vaccine.2012.09.027","article-title":"Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults","volume":"30","author":"Gogtay","year":"2012","journal-title":"Vaccine"},{"key":"2021110300345704200_CIT0012","article-title":"Franka R, Carson WC, Ellison JA, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017;2(3):48. Published 20 September 2017."},{"key":"2021110300345704200_CIT0013","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"2021110300345704200_CIT0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1746-6148-2-2","article-title":"A molecular epidemiological study of rabies epizootics in kudu (Tragelaphus strepsiceros) in Namibia","volume":"2","author":"Mansfield","year":"2006","journal-title":"BMC Vet Res"},{"key":"2021110300345704200_CIT0015","first-page":"1463","article-title":"Enzootic and epizootic rabies associated with vampire bats, Peru","volume-title":"Emerg Infect Dis","author":"Condori-Condori","year":"2013"},{"key":"2021110300345704200_CIT0016","first-page":"3","article-title":"Development in immunoprophylaxis against rabies for animals and humans","volume":"2","author":"Nandi","year":"2010","journal-title":"Avicenna J Med Biotechnol"},{"key":"2021110300345704200_CIT0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for post exposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021110300345704200_CIT0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/biol.1997.0117","article-title":"Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies","volume":"26","author":"Lang","year":"1998","journal-title":"Biologicals"},{"key":"2021110300345704200_CIT0019"},{"key":"2021110300345704200_CIT0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.47203\/IJCH.2018.v30i03.004","article-title":"Safety of new indigenous human rabies monoclonal antibody (RMAb) for post exposure prophylaxis","volume":"30","author":"Shivalingaiah","year":"2018","journal-title":"Indian J Comm Health"},{"key":"2021110300345704200_CIT0021","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/biol.1998.0156","article-title":"Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV)","volume":"26","author":"Lang","year":"1998","journal-title":"Biologicals"},{"key":"2021110300345704200_CIT0022","first-page":"655","article-title":"Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine","volume":"51","author":"Deshpande","year":"2003","journal-title":"J Assoc Physicians India"},{"key":"2021110300345704200_CIT0023","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa779\/33677674\/ciaa779.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e2722\/41057344\/ciaa779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e2722\/41057344\/ciaa779.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T22:56:32Z","timestamp":1666911392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/e2722\/5858415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,17]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa779","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,6,17]]}}}